Literature DB >> 11179385

Neutralization of Shiga toxins Stx1, Stx2c, and Stx2e by recombinant bacteria expressing mimics of globotriose and globotetraose.

A W Paton1, R Morona, J C Paton.   

Abstract

Strains of Escherichia coli producing Shiga toxins Stx1, Stx2, Stx2c, and Stx2d cause gastrointestinal disease and the hemolytic-uremic syndrome in humans. We have recently constructed a recombinant bacterium which displays globotriose (the receptor for these toxins) on its surface and adsorbs and neutralizes these Shiga toxins with very high efficiency. This agent has great potential for the treatment of humans with such infections. E. coli strains which cause edema disease in pigs produce a variant toxin, Stx2e, which has a different receptor specificity from that for the other members of the Stx family. We have now modified the globotriose-expressing bacterium such that it expresses globotetraose (the preferred receptor for Stx2e) by introducing additional genes encoding a N-acetylgalactosamine transferase and a UDP-N-acetylgalactosamine-4-epimerase. This bacterium had a reduced capacity to neutralize Stx1 and Stx2c in vitro, but remarkably, its capacity to bind Stx2e was similar to that of the globotriose-expressing construct; both constructs neutralized 98.4% of the cytotoxicity in lysates of E. coli JM109 expressing cloned stx2e. These data suggest that either globotriose- or globotetraose-expressing constructs may be suitable for treatment and/or prevention of edema disease in pigs.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11179385      PMCID: PMC98114          DOI: 10.1128/IAI.69.3.1967-1970.2001

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  21 in total

1.  Construction of vectors with the p15a replicon, kanamycin resistance, inducible lacZ alpha and pUC18 or pUC19 multiple cloning sites.

Authors:  M G Jobling; R K Holmes
Journal:  Nucleic Acids Res       Date:  1990-09-11       Impact factor: 16.971

2.  Effect of lipopolysaccharide core synthesis mutations on the production of Vibrio cholerae O-antigen in Escherichia coli K-12.

Authors:  R Morona; M H Brown; J Yeadon; M W Heuzenroeder; P A Manning
Journal:  FEMS Microbiol Lett       Date:  1991-08-15       Impact factor: 2.742

3.  Comparison of the glycolipid receptor specificities of Shiga-like toxin type II and Shiga-like toxin type II variants.

Authors:  J E Samuel; L P Perera; S Ward; A D O'Brien; V Ginsburg; H C Krivan
Journal:  Infect Immun       Date:  1990-03       Impact factor: 3.441

Review 4.  Shiga and Shiga-like toxins.

Authors:  A D O'Brien; R K Holmes
Journal:  Microbiol Rev       Date:  1987-06

5.  Molecular characterization of the locus encoding biosynthesis of the lipopolysaccharide O antigen of Escherichia coli serotype O113.

Authors:  A W Paton; J C Paton
Journal:  Infect Immun       Date:  1999-11       Impact factor: 3.441

6.  Cloning and sequencing of a Shiga-like toxin type II variant from Escherichia coli strain responsible for edema disease of swine.

Authors:  D L Weinstein; M P Jackson; J E Samuel; R K Holmes; A D O'Brien
Journal:  J Bacteriol       Date:  1988-09       Impact factor: 3.490

7.  Improved M13 phage cloning vectors and host strains: nucleotide sequences of the M13mp18 and pUC19 vectors.

Authors:  C Yanisch-Perron; J Vieira; J Messing
Journal:  Gene       Date:  1985       Impact factor: 3.688

8.  Globotetraosylceramide is recognized by the pig edema disease toxin.

Authors:  S DeGrandis; H Law; J Brunton; C Gyles; C A Lingwood
Journal:  J Biol Chem       Date:  1989-07-25       Impact factor: 5.157

9.  The assembly system for the outer core portion of R1- and R4-type lipopolysaccharides of Escherichia coli. The R1 core-specific beta-glucosyltransferase provides a novel attachment site for O-polysaccharides.

Authors:  D E Heinrichs; J A Yethon; P A Amor; C Whitfield
Journal:  J Biol Chem       Date:  1998-11-06       Impact factor: 5.157

Review 10.  Infection by verocytotoxin-producing Escherichia coli.

Authors:  M A Karmali
Journal:  Clin Microbiol Rev       Date:  1989-01       Impact factor: 26.132

View more
  24 in total

Review 1.  Designer probiotics: Development and applications in gastrointestinal health.

Authors:  Roy D Sleator
Journal:  World J Gastrointest Pathophysiol       Date:  2015-08-15

Review 2.  Bioengineered bugs expressing oligosaccharide receptor mimics: toxin-binding probiotics for treatment and prevention of enteric infections.

Authors:  Adrienne W Paton; Renato Morona; James C Paton
Journal:  Bioeng Bugs       Date:  2009-11-17

3.  Strategies to avoid Shiga toxin effects.

Authors:  Analia Etcheverria
Journal:  Virulence       Date:  2015       Impact factor: 5.882

4.  Shiga toxin subtypes display dramatic differences in potency.

Authors:  Cynthia A Fuller; Christine A Pellino; Michael J Flagler; Jane E Strasser; Alison A Weiss
Journal:  Infect Immun       Date:  2011-01-03       Impact factor: 3.441

5.  Prebiotic galactooligosaccharides reduce adherence of enteropathogenic Escherichia coli to tissue culture cells.

Authors:  Kari Shoaf; George L Mulvey; Glen D Armstrong; Robert W Hutkins
Journal:  Infect Immun       Date:  2006-09-18       Impact factor: 3.441

Review 6.  Targeting ricin to the ribosome.

Authors:  Kerrie L May; Qing Yan; Nilgun E Tumer
Journal:  Toxicon       Date:  2013-02-20       Impact factor: 3.033

7.  Functional characterization of Gne (UDP-N-acetylglucosamine-4-epimerase), Wzz (chain length determinant), and Wzy (O-antigen polymerase) of Yersinia enterocolitica serotype O:8.

Authors:  José Antonio Bengoechea; Elise Pinta; Tiina Salminen; Clemens Oertelt; Otto Holst; Joanna Radziejewska-Lebrecht; Zofia Piotrowska-Seget; Reija Venho; Mikael Skurnik
Journal:  J Bacteriol       Date:  2002-08       Impact factor: 3.490

8.  Functional expression of enterobacterial O-polysaccharide biosynthesis enzymes in Bacillus subtilis.

Authors:  Christina Schäffer; Thomas Wugeditsch; Paul Messner; Chris Whitfield
Journal:  Appl Environ Microbiol       Date:  2002-10       Impact factor: 4.792

9.  Stx2-specific human monoclonal antibodies protect mice against lethal infection with Escherichia coli expressing Stx2 variants.

Authors:  Abhineet S Sheoran; Susan Chapman; Pradeep Singh; Arthur Donohue-Rolfe; Saul Tzipori
Journal:  Infect Immun       Date:  2003-06       Impact factor: 3.441

Review 10.  Rational design of improved pharmabiotics.

Authors:  Roy D Sleator; Colin Hill
Journal:  J Biomed Biotechnol       Date:  2009-09-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.